Press releases & announcements
25 April, 2018
RhoVac AB (publ) (“RhoVac”) announced today, 25th April 2018, that the company has received an invitation to meet with the European Medicines Agency (EMA) to further discuss a phase IIb... [Read more]
9 April, 2018
RhoVac announces a rights issue of SEK 24.5 million aimed at strengthening business development activities
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL.... [Read more]
29 March, 2018
RhoVac announces that the final patient in the clinical phase I/II study has had his/her blood sample taken
RhoVac AB (“RhoVac”) announced today 29th March 2018 that the last patient enrolled in the clinical phase I/II study with RhoVac’s drug candidate RV001, also had his/her blood sample drawn... [Read more]
RhoVac in Brief
RhoVac undertakes research and development of therapeutic cancer vaccines. The primary candidate, RV001, targets RhoC which is overexpressed in cancer cells with metastatic potential.
Because most cancers form metastases, RV001 can potentially be used to treat a broad range of cancers. RhoVac's concept focuses on eliminating metastatic cancer cells that may escape treatment of the parent tumour via other methods. Because RhoC is not expressed in the parent tumour, the company goal is to use the developed product in combination with another therapy -- specifically, treatment of the parent tumour by e.g. surgery, radiotherapy or chemotherapy together with treatment with the therapeutic cancer vaccine to combat metastasis.